GNR-139 not checked

AO GENERIUM

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
10 in total · 9 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“GNR-139 is being developed as a biosimilar to the reference medicinal product Eylea®”In the company’s words, NCT07844148 on ClinicalTrials.gov
Tested for
nAMD
Main trialPhase 3
“This is a multicenter, randomized, double-blind study designed to compare the efficacy and safety of the investigational drug GNR-139 with the reference drug Eylea in treatment-naive patients with neovascular age-related macular degeneration (nAMD). Participants will be randomly assigned to receive either GNR-139 or Eylea. Neither the participants nor the study doctors will know which treatment is being administered. Both drugs will be given as an intravitreal injection dose of 8 mg (0.07 mL at a concentration of 114.3 mg/mL). Patients meeting the eligibility criteria will be randomised in…”In the company’s words, NCT07844148 on ClinicalTrials.gov
Other names
aflibercept
Copy of
Eylea (Regeneron Pharmaceuticals)Tested side by side with the original in NCT07844148

Other drugs for nAMD

All 3 drugs for nAMD

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Recruiting May 2028 A Study to Compare GNR-139 and Eylea® in Patients With nAMD
Phase 3Ended not given Single-arm, open label, multicenter clinical study to evaluate the handling and safety of AVT06 pre-filled syringe (PFS) in subjects with chorioretinal vascular disease followed by an optional extension phase of AVT06 pre-filled syringe (PFS).
Phase 3Ended not given TELeMAC - Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1
Phase 3Ended not given An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study
Phase 3Ended not given Neovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroid melanoma
Phase 3/4Ended not given Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN)
Phase 2Ended not given Spontaneous Retinal Arterial Pulsations (SRAPs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVOs) in patients treated or not with intravitreal injections of aflibercept
Phase 4Authorised not given Personalized treatment aided by automated analysis of fluid in active neovascular age-related macular degeneration (nAMD) in a prospective, multicenter, randomized study
Phase 2Authorised not given Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2
Phase 4Authorised not given Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow GNR-139

Following is part of Solo: you see every change to GNR-139 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in